These considerations may have possible important consequences in the dysregulated APP metabolism occurring in several conditions (e.g., from physiological aging and AD to brain injury response) [141] and point towards possible sAPPα-based therapeutic strategies. This evidence concerns the gene APP and Alzheimer disease.